Literature DB >> 12204718

Putative side effects of prostaglandin analogs.

Robert A Schumer1, Carl B Camras, Agneta K Mandahl.   

Abstract

Anecdotal case reports describe the occurrence of cystoid macular edema, iritis, herpes simplex keratitis, periocular skin darkening, and headaches in patients treated with prostaglandin analogs for glaucoma. The purpose of this article is to critically analyze these anecdotal case reports in light of a few well-controlled, randomized clinical studies to determine whether conclusions can be made about a causal relationship between the use of prostaglandin analogs and the occurrence of these side effects. None of these putative side effects has been proven to be causally related to latanoprost therapy using valid scientific methodology. These possible side effects occur rarely. Cystoid macular edema, iritis, and herpes simplex keratitis occur in eyes with risk factors. To scientifically establish a causal relationship between drug therapy and rare side effects, repeated rechallenging with masked controls is required. With rare exception, such methodology has not been used with any of these putative side effects. Nevertheless, even without firm establishment of a causal relationship, caution is advised with the use of prostaglandin analogs in eyes with risk factors for cystoid macular edema, iritis, and herpes simplex keratitis until properly designed, large, controlled studies provide more definitive information.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204718     DOI: 10.1016/s0039-6257(02)00328-4

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  18 in total

Review 1.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

2.  Short- and long-term corneal vascular effects of tafluprost eye drops.

Authors:  Deniz Hos; Konrad R Koch; Felix Bock; Rafael S Grajewski; Thomas S Dietlein; Claus Cursiefen; Ludwig M Heindl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-28       Impact factor: 3.117

Review 3.  Pharmacologic management of glaucoma in childhood.

Authors:  Will Moore; Ken K Nischal
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  Cystoid macular oedema within 24 h after a single application of latanoprost.

Authors:  Vlassis G Grigoropoulos; Ioannis Emfietzoglou; Pantelis Nikolaidis; Panagiotis G Theodossiadis; George P Theodossiadis
Journal:  Int Ophthalmol       Date:  2008-04-03       Impact factor: 2.031

5.  Efficacy and safety of latanoprost in eyes with uveitic glaucoma.

Authors:  Nikos N Markomichelakis; Agori Kostakou; Ioannis Halkiadakis; Sonia Chalkidou; Dimitrios Papakonstantinou; Gerasimos Georgopoulos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-01-28       Impact factor: 3.117

6.  Serous retinal detachment in the macula related to latanoprost use.

Authors:  Berna Ozkan; V Levent Karabaş; Nurşen Yüksel; Yusuf Cağlar
Journal:  Int Ophthalmol       Date:  2007-09-05       Impact factor: 2.031

7.  Long-term therapeutic outcome of acute primary angle closure in Japanese.

Authors:  Akira Sawada; Akira Aoyama; Tetsuya Yamamoto; Naoyoshi Takatsuka
Journal:  Jpn J Ophthalmol       Date:  2007-10-05       Impact factor: 2.447

Review 8.  Graft failure: III. Glaucoma escalation after penetrating keratoplasty.

Authors:  Emily C Greenlee; Young H Kwon
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

Review 9.  [Secondary glaucoma in childhood uveitis].

Authors:  C Heinz; U Pleyer; P Ruokonnen; A Heiligenhaus
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

Review 10.  Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.

Authors:  Gábor Holló; Andreas Katsanos; Kostas G Boboridis; Murat Irkec; Anastasios G P Konstas
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.